NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.

Sharma P, Boyers D, Boachie C, et al. Elucigene FH20 and LIPOchip for the Diagnosis of Familial Hypercholesterolaemia: A Systematic Review and Economic Evaluation. Southampton (UK): NIHR Journals Library; 2012 Mar. (Health Technology Assessment, No. 16.17.)

Cover of Elucigene FH20 and LIPOchip for the Diagnosis of Familial Hypercholesterolaemia: A Systematic Review and Economic Evaluation

Elucigene FH20 and LIPOchip for the Diagnosis of Familial Hypercholesterolaemia: A Systematic Review and Economic Evaluation.

Show details

Appendix 13Age-specific analysis for index cases and relatives

In each of the following analyses, costs and incremental costs are rounded to the nearest whole pounds sterling. QALYs and incremental QALYs are rounded to the nearest whole QALY. ICERs are also rounded to the nearest £/QALY gained from the economic model. Therefore, the ratio of reported costs divided by reported QALYs may not always reflect an exact recalculation of the numbers from the tables. This is caused due to rounding; however, the ICERs reported are the true and exact ICERs as generated by the economic model and so minimise the impact of rounding errors on our results.

TABLE 42aAnalysis of index cases and relatives cascaded from index case aged 15 years

Test strategyTotal costs (£)Total QALYsIncremental costs (£)Incremental QALYsICER (£/QALY)
Elucigene FH2048,382,90239,682
LDL-C49,384,42337,360DominatedDominatedDominated
Elucigene FH20_MLPA49,596,34840,338ExtExt DomExt Dom
LIPOchip51,840,31441,532Ext DomExt DomExt Dom
Elucigene FH20_LIPOchip51,912,01441,532DominatedDominatedDominated
LIPOchip platform – Spain52,719,93942,0314,337,03823501846
LIPOchip_MLPA53,046,20042,189Ext DomExt DomExt Dom
Elucigene FH20_LIPOchip_MLPA53,117,90042,189DominatedDominatedDominated
CGA54,037,15342,6881,317,2136572005
Elucigene FH20_CGA54,084,70342,688DominatedDominatedDominated
LIPOchip_CGA54,208,00342,688DominatedDominatedDominated
Elucigene FH20_LIPOchip_CGA54,279,70342,688DominatedDominatedDominated

Ext Dom, extendedly dominated.

TABLE 42bAnalysis of index cases and relatives cascaded from index case aged 15 years (relevant comparison LDL-C)

TestTotal costs (£)Total QALYsIncremental costs (£)Incremental QALYsICER (£/QALY)
Elucigene FH2048,382,90239,682−1,001,5212321Dominant
LDL-C49,384,42337,360
LIPOchip platform – Spain52,719,93942,0313,335,5164671714
CGA54,037,15342,6884,652,7305328873

TABLE 43aAnalysis of index cases and relatives cascaded from index case aged 30 years

Test strategyTotal costs (£)Total QALYsIncremental costs (£)Incremental QALYsICER (£/QALY)
Elucigene FH2072,338,13444,143
LDL-C72,671,49243,013DominatedDominatedDominated
Elucigene FH20_MLPA73,626,95044,473Ext DomExt DomExt Dom
LIPOchip76,007,92345,073Ext DomExt DomExt Dom
Elucigene FH20_LIPOchip76,079,62345,073DominatedDominatedDominated
LIPOchip platform – Spain76,944,81445,3244,606,68011813901
LIPOchip_MLPA77,289,17945,403Ext DomExt DomExt Dom
Elucigene FH20_LIPOchip_MLPA77,360,87945,403DominatedDominatedDominated
CGA78,337,39745,6541,392,5833304219
Elucigene FH20_CGA78,384,94745,654DominatedDominatedDominated
LIPOchip_CGA78,508,24745,654DominatedDominatedDominated
Elucigene FH20_LIPOchip_CGA78,579,94745,654DominatedDominatedDominated

Ext Dom, extendedly dominated.

TABLE 43bAnalysis of index cases and relatives cascaded from index case aged 30 years (relevant comparison LDL-C)

TestTotal costs (£)Total QALYsIncremental costs (£)Incremental QALYsICER (£/QALY)
Elucigene FH2072,338,13444,143−333,3581130Dominant
LDL-C72,671,49243,013
LIPOchip platform – Spain76,944,81445,3244,273,32223111849
CGA78,337,39745,6545,665,90526412145

TABLE 44aAnalysis of index cases and relatives cascaded from index case aged 65 years

Test strategyTotal costs (£)Total QALYsIncremental costs (£)Incremental QALYsICER (£/QALY)
LDL-C58,704,11434,704
Elucigene FH2060,370,42236,1581,666,30814541146
Elucigene FH20_MLPA61,804,33836,580Ext DomExt DomExt Dom
LIPOchip64,449,07737,346Ext DomExt DomExt Dom
Elucigene FH20_LIPOchip64,520,77737,346DominatedDominatedDominated
LIPOchip platform – Spain65,496,21637,6675,125,79415083398
LIPOchip_MLPA65,875,43337,768Ext DomExt DomExt Dom
Elucigene FH20_LIPOchip_MLPA65,947,13337,768DominatedDominatedDominated
CGA67,033,89938,0881,537,6834223647
Elucigene FH20_CGA67,081,44938,088DominatedDominatedDominated
LIPOchip_CGA67,204,74938,088DominatedDominatedDominated
Elucigene FH20_LIPOchip_CGA67,276,44938,088DominatedDominatedDominated

Ext Dom, extendedly dominated.

TABLE 44bAnalysis of index cases and relatives cascaded from index case aged 65 years (relevant comparison LDL-C)

TestTotal costs (£)Total QALYsIncremental costs (£)Incremental QALYsICER (£/QALY)
LDL-C58,704,11434,704
Elucigene FH2060,370,42236,1581,666,30814541146
LIPOchip platform – Spain65,496,21637,6676,792,10229622293
CGA67,033,89938,0888,329,78633842462

TABLE 45aAnalysis of index cases and relatives cascaded from index case aged 75 years

Test strategyTotal costs (£)Total QALYsIncremental costs (£)Incremental QALYsICER (£/QALY)
LDL-C33,141,93926,128
Elucigene FH2034,672,01528,4641,530,0762336655
Elucigene FH20_MLPA35,813,45629,123Ext DomExt DomExt Dom
LIPOchip37,926,53230,319Ext DomExt DomExt Dom
Elucigene FH20_LIPOchip37,998,23230,319DominatedDominatedDominated
LIPOchip platform – Spain38,751,44830,8204,079,43223551732
LIPOchip_MLPA39,060,41330,978Ext DomExt DomExt Dom
Elucigene FH20_LIPOchip_MLPA39,132,11330,978DominatedDominatedDominated
CGA39,996,65631,4781,245,2096581891
Elucigene FH20_CGA40,044,20631,478DominatedDominatedDominated
LIPOchip_CGA40,167,50631,478DominatedDominatedDominated
Elucigene FH20_LIPOchip_CGA40,239,20631,478DominatedDominatedDominated

Ext Dom, extendedly dominated.

TABLE 45bAnalysis of index cases and relatives cascaded from index case aged 75 years (relevant comparison LDL-C)

TestTotal costs (£)Total QALYsIncremental costs (£)Incremental QALYsICER (£/QALY)
LDL-C33,141,93926,128
Elucigene FH2034,672,01528,4641,530,0762336655
LIPOchip platform – Spain38,751,44830,8205,609,50946921196
CGA39,996,65631,4786,854,71753501281

TABLE 46aAnalysis of index cases and relatives cascaded from index case aged 85 years

Test strategyTotal costs (£)Total QALYsIncremental costs (£)Incremental QALYsICER (£/QALY)
LDL-C30,692,28817,638
Elucigene FH2031,577,62218,313885,3346751312
Elucigene FH20_MLPA32,278,76918,501Ext DomExt DomExt Dom
LIPOchip33,591,47218,844Ext DomExt DomExt Dom
Elucigene FH20_LIPOchip33,663,17218,844DominatedDominatedDominated
LIPOchip platform – Spain34,081,85018,9872,504,2286743715
LIPOchip_MLPA34,285,05919,032Ext DomExt DomExt Dom
Elucigene FH20_LIPOchip_MLPA34,356,75919,032DominatedDominatedDominated
CGA34,886,76419,175804,9141884272
Elucigene FH20_CGA34,934,31419,175DominatedDominatedDominated
LIPOchip_CGA35,057,61419,175DominatedDominatedDominated
Elucigene FH20_LIPOchip_CGA35,129,31419,175DominatedDominatedDominated

Ext Dom, extendedly dominated.

TABLE 46bAnalysis of index cases and relatives cascaded from index case aged 85 years (relevant comparison LDL-C)

TestTotal costs (£)Total QALYsIncremental costs (£)Incremental QALYsICER (£/QALY)
LDL-C30,692,28817,638
Elucigene FH2031,577,62218,313885,3346751312
LIPOchip platform – Spain34,081,85018,9873,389,56213492513
CGA34,886,76419,1754,194,47615372728
© 2012, Crown Copyright.

Included under terms of UK Non-commercial Government License.

Bookshelf ID: NBK97928

Views

  • PubReader
  • Print View
  • Cite this Page
  • PDF version of this title (2.1M)

Other titles in this collection

Recent Activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...